To investigate the efficacy of novel first-in-class triple targeted PI3K/mTOR/PIM inhibitor (IBL-301) (Inflection Biosciences Ltd., Dublin, Ireland) in comparison to single targeted agents pan-PI3K inhibitor (GDC-0941) and pan-PIM kinase inhibitor (AZD1208), IC50 values were determined via the CellTiter-Glo® cell viability assay in Calu-6 and H1975 NSCLC cell lines (Figure 2A,B). This evidence concerns the gene PIK3CA and non-small cell lung carcinoma.